These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7734209)

  • 1. Multiple endocrine neoplasia type 2.
    Forster-Gibson CJ; Mulligan LM
    Eur J Cancer; 1994; 30A(13):1969-74. PubMed ID: 7734209
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medullary thyroid gland carcinoma. Sporadic/familial. Screening when and why?].
    Frilling A; Liedke MO
    Internist (Berl); 1998 Jun; 39(6):588-91. PubMed ID: 9677514
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2.
    Mulligan LM; Ponder BA
    J Clin Endocrinol Metab; 1995 Jul; 80(7):1989-95. PubMed ID: 7608246
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
    Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
    Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prophylactic total thyroidectomy in children and adolescents with genetic mutations in the RET-protooncogene].
    Spinelli C; Puccini M; Bertocchini A; Lima M; Pacini F; Miccoli P
    Pediatr Med Chir; 2002; 24(1):53-7. PubMed ID: 11938683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
    Hofstra RM; van der Luijt RB; Lips CJ
    Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [One gene--four diseases: on the importance of mutations in the ret gene in MEN 2A, MEN 2B, Hirschsprung disease and medullary thyroid carcinoma].
    Fehmann HC; Göke B
    Z Gastroenterol; 1994 Jul; 32(7):416-7. PubMed ID: 7975780
    [No Abstract]   [Full Text] [Related]  

  • 9. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple endocrine neoplasia syndromes revisited. Clinical, morphologic, and molecular features.
    DeLellis RA
    Lab Invest; 1995 May; 72(5):494-505. PubMed ID: 7745945
    [No Abstract]   [Full Text] [Related]  

  • 11. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children.
    van Heurn LW; Schaap C; Sie G; Haagen AA; Gerver WJ; Freling G; van Amstel HK; Heineman E
    J Pediatr Surg; 1999 Apr; 34(4):568-71. PubMed ID: 10235324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer.
    Blaugrund JE; Johns MM; Eby YJ; Ball DW; Baylin SB; Hruban RH; Sidransky D
    Hum Mol Genet; 1994 Oct; 3(10):1895-7. PubMed ID: 7849720
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The direct gene test in familial medullary thyroid gland carcinoma and in MEN syndromes. Detection of mutations in the ret proto-oncogene saves screening studies].
    Stuhrmann M
    Fortschr Med; 1995 Dec; 113(35-36):503-6. PubMed ID: 8582691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
    Ponder BA
    Cancer Surv; 1995; 25():195-205. PubMed ID: 8718519
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2.
    Learoyd DL; Marsh DJ; Richardson AL; Twigg SM; Delbridge L; Robinson BG
    Arch Surg; 1997 Sep; 132(9):1022-5. PubMed ID: 9301617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Cold" single-strand conformational variants for mutation analysis of the RET protooncogene.
    Musholt PB; Musholt TJ; Goodfellow PJ; Zehnbauer BA; Wells SA; Moley JF
    Surgery; 1997 Aug; 122(2):363-70; discussion 370-1. PubMed ID: 9288142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.